Pacific BioLogic's dietary supplements had manufacturing violations and disease claims making them unapproved drugs.
What happened
FDA inspected the Concord, CA facility June 1 through 29, 2023 and found significant violations of current good manufacturing practice (CGMP) for dietary supplements, including missing specifications, master manufacturing records, batch production records, complaint records, reserve samples, and quality control checks. FDA also reviewed labels and websites in July 2023 and found disease claims making several supplements unapproved new drugs, plus labeling violations; it said the company’s July 14, 2023 response was inadequate.
What FDA found
Website claims that products treat diseases made several supplements unapproved new drugs and drugs with inadequate directions.
FD&C Act §§ 201(g)(1)(B), 201(p), 301(d), 502(f)(1), 505(a) [21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 352(f)(1), 355(a)]The company did not establish required specifications for components, labels and packaging, and finished dietary supplements.
21 CFR 111.70(b), (d), (e)The company did not prepare written master manufacturing records for some products and its records for others lacked required content.
21 CFR 111.205(a), 111.210The company did not prepare a batch production record for any finished product.
21 CFR 111.255(a)The company failed to review and record complaints, document returned-product disposition, keep reserve samples, and ensure quality control matched components to labels.
21 CFR 111.560(a)(1), 111.570(b)(2), 111.535(b)(2), 111.83(a), 111.105Labels failed to declare common or usual ingredient names and plant parts as required.
FD&C Act §§ 403(i)(2), 403(s)(2)(C) [21 U.S.C. §§ 343(i)(2), 343(s)(2)(C)]; 21 CFR 101.36, 101.4(h)
What FDA wants
FDA tells the company to correct the cited drug and manufacturing violations and provide adequate documentation; no response deadline is stated in the provided letter.
Who should pay attention
- contract manufacturers that encapsulate or bottle supplements for this firm
- retailers and distributors selling Pacific BioLogic products
- consumers using supplements marketed for heart disease, headaches, pain, or immune conditions
This is a summary. Read the original letter on fda.gov.